Home Cart 0 Sign in  
X

[ CAS No. 4664-01-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 4664-01-1
Chemical Structure| 4664-01-1
Chemical Structure| 4664-01-1
Structure of 4664-01-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 4664-01-1 ]

Related Doc. of [ 4664-01-1 ]

Alternatived Products of [ 4664-01-1 ]

Product Details of [ 4664-01-1 ]

CAS No. :4664-01-1 MDL No. :MFCD00013439
Formula : C7H4N2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :SJSABZBUTDSWMJ-UHFFFAOYSA-N
M.W : 148.12 Pubchem ID :72926
Synonyms :

Calculated chemistry of [ 4664-01-1 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 39.61
TPSA : 59.06 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.45 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.59
Log Po/w (XLOGP3) : -0.35
Log Po/w (WLOGP) : -0.42
Log Po/w (MLOGP) : 0.06
Log Po/w (SILICOS-IT) : 1.05
Consensus Log Po/w : 0.19

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.94
Solubility : 16.9 mg/ml ; 0.114 mol/l
Class : Very soluble
Log S (Ali) : -0.43
Solubility : 55.3 mg/ml ; 0.373 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.38
Solubility : 0.61 mg/ml ; 0.00412 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.37

Safety of [ 4664-01-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 4664-01-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 4664-01-1 ]
  • Downstream synthetic route of [ 4664-01-1 ]

[ 4664-01-1 ] Synthesis Path-Upstream   1~14

  • 1
  • [ 4664-01-1 ]
  • [ 40107-95-7 ]
YieldReaction ConditionsOperation in experiment
17%
Stage #1: for 24 h; Reflux
Stage #2: With calcium chloride In dichloromethane
To a solution of 3,4-pyridindicarboxamide (0.40 g, 2.7 mmol, 1 eq) in acetic acid (12 mL), zinc (0.78 g, 11.9 mmol, 4.4 eq) was added and the suspension was heated at reflux for 24 h.
After cooling at room temperature, the mixture was filtered off through a Celite pad.
The filtrate was evaporated and the residue was taken up with CH2Cl2.
To this solution CaCl2 was added and the suspension was filtered.
The filtrate was evaporated and the residue was purified by column chromatography using EtOAc/MeOH 95/5 as eluant to give 10 as yellowish solid after crystallization with EtOH (0.061 g, 17percent). Mp. 190-193 °C dec. 1H NMR (300 MHz, DMSO-d6) δ 8.84 (s, 1-H), 8.70 (br d, 2-H), 7.62 (d, J = 5.5 Hz, 1-H), 4.42 (s, 2-H); 13C NMR (75 MHz, DMSO-d6) δ 169.1, 153.3, 151.6, 145.3, 129.0, 119.9, 45.2; GC-MS m/z 134 (M)+; IR (KBr) 2856, 1728, 1692, 1455, 1206, 1026 cm-1. Anal. Calcd for C7H6N2O: C, 62.68; H, 4.51; N, 20.88. Found: C, 62.75; H, 4.50; N, 20.63.
Reference: [1] European Journal of Medicinal Chemistry, 2012, vol. 55, p. 58 - 66,9
[2] Patent: WO2005/103003, 2005, A2, . Location in patent: Page/Page column 106
  • 2
  • [ 490-11-9 ]
  • [ 4664-01-1 ]
YieldReaction ConditionsOperation in experiment
95.1%
Stage #1: at 140 - 150℃;
Stage #2: at 140℃; for 3 h;
A suspension of cinchomeronic acid (30)(50 g, 300 mmol) in acetic anhydride (123.5 g, 1200 mmol) was heated to reflux (140-150° C.) until all solid material dissolved and the mixture was homogeneous.
The mixture was then cooled and concentrated in vacuo.
Acetamide (50 g, 846 mmol) was then added and the mixture heated to 140° C. for 3 hours whereupon it was then cooled to room temperature.
The solid residue that formed upon cooling was pulverized and triturated with water (100 ml), filtered and washed with more water and dried in a desiccator to give the title compound (42.26 g, 95.1percent) in suitably pure form to be used without any further purification. m/z (LC-MS, ESP): 149 [M+H]+, R/T=0.44 mins.
Reference: [1] Patent: US2006/199804, 2006, A1, . Location in patent: Page/Page column 29
[2] Acta Chimica Hungarica, 1983, vol. 112, # 4, p. 487 - 500
  • 3
  • [ 4664-08-8 ]
  • [ 4664-01-1 ]
Reference: [1] Acta Chimica Hungarica, 1983, vol. 112, # 4, p. 487 - 500
[2] Tetrahedron Letters, 1993, vol. 34, # 39, p. 6225 - 6228
[3] Farmaco, Edizione Scientifica, 1980, vol. 35, # 11, p. 940 - 944
[4] Acta Poloniae Pharmaceutica, 1995, vol. 52, # 3, p. 245 - 248
  • 4
  • [ 1678-52-0 ]
  • [ 102-06-7 ]
  • [ 4664-01-1 ]
  • [ 65252-12-2 ]
  • [ 76240-10-3 ]
  • [ 76240-09-0 ]
Reference: [1] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1980, p. 1667 - 1670
  • 5
  • [ 60-35-5 ]
  • [ 4664-08-8 ]
  • [ 4664-01-1 ]
Reference: [1] Journal of Organic Chemistry, 1949, vol. 14, p. 97,101
  • 6
  • [ 583-58-4 ]
  • [ 7584-05-6 ]
  • [ 4664-01-1 ]
Reference: [1] Russian Journal of General Chemistry, 2012, vol. 82, # 12, p. 1987 - 1993[2] Zh. Obshch. Khim., 2012, vol. 82, # 12, p. 2033 - 2039,7
  • 7
  • [ 4664-01-1 ]
  • [ 7579-20-6 ]
YieldReaction ConditionsOperation in experiment
100% With bromine; sodium hydroxide In water at 90℃; for 0.666667 h; Cooling with ice Step 1
To 10percent aqueous sodium hydroxide solution (100 mL) was added bromine (1.93 mL, 38.6 mmol) under ice-cooling, and 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione (5.20 g, 35.1 mmol) was subsequently added. 10percent-Aqueous sodium hydroxide solution (60 mL) was added to the reaction mixture, and the mixture was stirred with heating at 90° C. for 40 min.
After allowing to cool to room temperature, 50percent sulfuric acid was added to adjust the reaction mixture to pH 3.
The precipitated insoluble material was collected by filtration, and the solid was washed with water to give 3-aminoisonicotinic acid as a pale-yellow powder (5.00 g, 100percent).
1H-NMR (200 MHz, DMSO-d6)
δ: 7.46 (1H, d, J=5.1 Hz), 7.73 (1H, d, J=5.1 Hz), 8.21 (1H, s).
68.33%
Stage #1: With sodium hydroxide; bromine In water at 7 - 80℃; for 0.5 h;
Stage #2: With acetic acid In water at 37℃;
NaOH (10percent aqueous, 640 ml) was cooled to 7° C. and bromine (15 ml, 286.82 mmol) added dropwise. Pyrrolo[3,4-c]pyridine-1,3-dione (41.711 g, 281.6 mmol) was then added to the reaction mixture before it was heated to 80° C. for 30 minutes.
After this time the reaction was allowed to warm to 37° C. and the pH modified to 5.5 by the addition of acetic acid (70 ml).
A suspension formed that was removed by filtration and washed with 20 ml of ice cold methanol to give the title compound (26.58 g, 68.33percent) in a suitably clean form to be used without any further purification. m/z (LC-MS, ESP): 139 [M+H]+, R/T=0.72 mins.
67%
Stage #1: With sodium hydroxide; bromine In water at 0 - 80℃; for 0.75 h;
Stage #2: With acetic acid In water
Bromine (3. 5 ml, 69.0 mmol) was added to a solution of 10 percent aqueous sodium hydroxide (120 ml) at 0 C to give a pale yellow solution. To this solution was added 3,4-pyridinedicarboximide (10 g, 67. 5 mmol) and the reaction was heated at 80 C for 45 min. The reaction was cooled in a water bath and acidified by the addition of acetic acid (12. 5 ml) causing precipitation. The solid was collected, rinsed with water(50 ml), thenMeOH(50 ml) and dried to give the title compound as a beige solid (6.28 g, 67 percent).1H NMR (360 MHz, DMSO)5 8. 06 (1H, s), 7.60(1H, d,J5. 1), 7.34(1H, d,J5. 1), 3.19 (2H, brs). M/z (ES+) 139 (M+H+).
64%
Stage #1: With sodium hydroxide; bromine In water at 80℃; for 1.1667 h;
Stage #2: With acetic acid In water at 20℃; for 0.166667 h;
Following the procedures of Zhou et al (2001) Bioorg. Med. Chem. Lett.9(8):2061-2071, bromine (1.22 ml, 23.9 mmol) was slowly added to a cooled (50C) 2.5N solution of NaOH (60 ml, 150 mmol) and after stirring for 5 minutes pyrrolo[3,4-c]pyridine- 1,3-dione (3.5 g, 23.6 mmol) was added. The temperature was raised to 8O0C and the mixture was stirred for 1 hour before being cooled to ambient temperature. Acetic acid (5.9 ml, 98.3 mmol) was cautiously added (N.B.: gas evolution) and the solution stirred for 10 minutes whereby a precipitate formed that was collected by filtration. The solid was washed with water (20 ml) and MeOH (20 ml) then dried to afford the title compound as a yellow solid (2.1 g, 64percent).
62% With sodium hydroxide; bromine In water at 0 - 80℃; for 0.75 h; A solution of10percent aqueousNaOH (416 mL) was cooled to0 C and treated with bromine (28.2 g 176 mmol) portionwise via pipette while keeping the temperature below 5 C. To this mixture was added 3,4-pyridinedicarboximide (25.78 g, 174mmol), and the cooling bath was removed. The reaction was heated to80 C for 45 min, then allowed to cool in an ice bath. When the temperature fell to 60 C, the dropwise addition of HOAc (50 mL) was started. Cooling was continued until the temperature reached 15 C. A yellow precipitate formed. The solid was filtered, rinsed with water, then dried under vacuum to give 14.9 g of product (108 mmol,62percent). 1NMR IS-MS, m/e 139(m+1)
57% With bromine In sodium hydroxide Preparation 18
3-Aminopyridine-4-carboxylic acid
To an ice cold mixture of 3,4-pyridinedicarboximide (5.2 g, 35.11 mmol) in 10percent sodium hydroxide (85 mL) was added bromine (1.84 mL, 35.8 mmol), dropwise.
The resulting solution was heated to 80° C. for 1 hour, cooled on ice, and the acidity was carefully adjusted to pH 5.5 with acetic acid.
The precipitate was collected, washed well with water and air dried to afford 3-aminopyridine-4-carboxylic acid (2.74 g, 57percent).
NMR (DMSO d6) δ8.20 (s, 1H), 7.72 (d, J=5 Hz, 1H), 7.45 (d, J=5 Hz, 1H).
The material was used without purification.
57%
Stage #1: With sodium hydroxide; bromine In water at 7 - 85℃; for 1.5 h;
Stage #2: With acetic acid In water at 20 - 30℃;
Step A: 3-Aminoisonicotinic acid: 2H-Pyrrolo[3,4-c]pyridine-1,3-dione (204.16 g, 1378.4 mmol) was dissolved in 10percent NaOH (3.3 L) and the solution was cooled to an internal temperature of 7° C. (ice/salt bath). Bromine (73.424 mL, 1433.5 mmol) was added dropwise while maintaining the internal temperature below 10° C. After completion of the addition, the reaction was heated to an internal temperature of 80-85° C. for 90 minutes. The reaction mixture was cooled to 20-30° C. in an ice bath then acetic acid (323.21 mL, 5651.2 mmol) was added dropwise. The reaction was stirred and cooled to 5° C. The solids were collected by vacuum filtration, washed with cold water then air-dried to provide the product (108.86 g, 57percent).
57% With bromine In sodium hydroxide Preparation 18
3-Aminopyridine-4-carboxylic acid
To an ice cold mixture of 3,4-pyridinedicarboximide (5.2 g, 35.11 mmol) in 10percent sodium hydroxide (85 mL) was added bromine (1.84 mL, 35.8 mmol), dropwise.
The resulting solution was heated to 80° C. for 1 hour, cooled on ice, and the acidity was carefully adjusted to pH 5.5 with acetic acid.
The precipitate was collected, washed well with water and air dried to afford 3-aminopyridine-4-carboxylic acid (2.74 g, 57percent).
1H NMR (DMSO d6) δ8.20 (s,1 H), 7.72 (d, J=5 Hz, 1 H), 7.45 (d, J=5 Hz, 1 H).
The material was used without purification.

Reference: [1] Patent: US2015/329556, 2015, A1, . Location in patent: Paragraph 1612-1614
[2] Bioorganic and Medicinal Chemistry, 2001, vol. 9, # 8, p. 2061 - 2071
[3] Australian Journal of Chemistry, 1993, vol. 46, # 7, p. 987 - 993
[4] Tetrahedron Letters, 1993, vol. 34, # 39, p. 6225 - 6228
[5] Patent: US2006/199804, 2006, A1, . Location in patent: Page/Page column 29
[6] Patent: WO2005/49613, 2005, A1, . Location in patent: Page/Page column 38
[7] Patent: WO2008/24725, 2008, A1, . Location in patent: Page/Page column 67
[8] Patent: WO2005/49604, 2005, A2, . Location in patent: Page/Page column 69
[9] Journal of Medicinal Chemistry, 2017, vol. 60, # 16, p. 6942 - 6990
[10] Patent: US5962457, 1999, A,
[11] Patent: US2007/49603, 2007, A1, . Location in patent: Page/Page column 78; 30
[12] Patent: US6323208, 2001, B1,
[13] Patent: WO2004/831, 2003, A1, . Location in patent: Page 22
[14] Patent: WO2008/108957, 2008, A2, . Location in patent: Page/Page column 95
  • 8
  • [ 4664-01-1 ]
  • [ 7579-20-6 ]
YieldReaction ConditionsOperation in experiment
57% With bromine In sodium hydroxide Preparation 18
3-Aminopyridine-4-carboxvlic acid
To an ice cold mixture of 3,4-pyridinedicarboximide (5.2 g, 35.11 mmol) in 10percent sodium hydroxide (85 mL) was added bromine (1.84 mL, 35.8 mmol), dropwise.
The resulting solution was heated to 80°C for 1 hour, cooled on ice, and the acidity was carefully adjusted to pH 5.5 with acetic acid.
The precipitate was collected, washed well with water and air dried to afford 3-aminopyridine4-carboxylic acid (2.74 g, 57percent).
NMR (DMSO d6) δ 8.20 (s, 1 H), 7.72 (d, J = 5 Hz, 1 H), 7.45 (d, J = 5 Hz, 1 H).
The material was used without purification.
Reference: [1] Patent: EP807633, 1997, A2,
  • 9
  • [ 4664-01-1 ]
  • [ 10128-71-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2017, vol. 60, # 16, p. 6942 - 6990
  • 10
  • [ 67-56-1 ]
  • [ 4664-01-1 ]
  • [ 1356116-51-2 ]
  • [ 1356116-53-4 ]
  • [ 55279-30-6 ]
Reference: [1] Organic Letters, 2012, vol. 14, # 3, p. 946 - 949
  • 11
  • [ 4664-01-1 ]
  • [ 14208-83-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2001, vol. 9, # 8, p. 2061 - 2071
[2] Australian Journal of Chemistry, 1993, vol. 46, # 7, p. 987 - 993
  • 12
  • [ 4664-01-1 ]
  • [ 152398-05-5 ]
Reference: [1] Patent: US2003/45519, 2003, A1,
  • 13
  • [ 4664-01-1 ]
  • [ 152398-05-5 ]
Reference: [1] Australian Journal of Chemistry, 1993, vol. 46, # 7, p. 987 - 993
[2] Patent: WO2008/108957, 2008, A2,
  • 14
  • [ 4664-01-1 ]
  • [ 5655-00-5 ]
YieldReaction ConditionsOperation in experiment
62%
Stage #1: at 100℃; for 4 h;
Step lTo a solution of compound [137] (3 g, 20.2 mmol, leq) in glacial acetic acid (30 ml), Zn dust (5.26 g, 81.0 mmol, 4 eq.) was added and the reaction mixture was refluxed at 100 °C for 4 h. The reaction mixture was cooled to room temperature and the solvent was evaporated. The reaction mass was made basic with aqueous NaHC03 to pH 8 and extracted with chloroform. The aqueous layer was concentrated and further extracted with chloroform. The combined organic layer was dried over Na2S04 and evaporated to give [138] as a peach white solid (1.7 g, 62percent).ESIMS: 135 (M+ + 1)
Reference: [1] Patent: WO2012/101654, 2012, A2, . Location in patent: Page/Page column 72
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 4664-01-1 ]

Amides

Chemical Structure| 40107-95-7

[ 40107-95-7 ]

1H-Pyrrolo[3,4-c]pyridin-3(2H)-one

Similarity: 0.97

Chemical Structure| 3034-31-9

[ 3034-31-9 ]

N-Phenyl isonicotinicamide

Similarity: 0.81

Chemical Structure| 1453-82-3

[ 1453-82-3 ]

Isonicotinamide

Similarity: 0.78

Chemical Structure| 4663-99-4

[ 4663-99-4 ]

Pyridine-3,5-dicarboxamide

Similarity: 0.77

Chemical Structure| 62936-56-5

[ 62936-56-5 ]

Sodium 4-(nicotinamido)butanoate

Similarity: 0.76

Related Parent Nucleus of
[ 4664-01-1 ]

Other Aromatic Heterocycles

Chemical Structure| 40107-95-7

[ 40107-95-7 ]

1H-Pyrrolo[3,4-c]pyridin-3(2H)-one

Similarity: 0.97

Chemical Structure| 40107-93-5

[ 40107-93-5 ]

6,7-Dihydro-5H-pyrrolo[3,4-b]pyridin-5-one

Similarity: 0.73

Chemical Structure| 155058-02-9

[ 155058-02-9 ]

7,8-Dihydro-1,6-naphthyridin-5(6H)-one

Similarity: 0.72

Chemical Structure| 6000-50-6

[ 6000-50-6 ]

2,3-Dihydro-1H-pyrrolo[3,4-c]pyridine dihydrochloride

Similarity: 0.71

Chemical Structure| 16952-65-1

[ 16952-65-1 ]

Pyrido[4,3-d]pyrimidine-2,4(1H,3H)-dione

Similarity: 0.71